Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2017 Feb 7;8:14232. doi: 10.1038/ncomms14232

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2017, The Author(s)

This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/

PMC Copyright notice

(a) Effect of small-molecule FPR agonists (both 1 μM, added on reoxygenation) on rat cardiomyocyte cTnI release subsequent to H–R; ^##P<0.01 versus sham and *P<0.05 versus vehicle-treated H–R in paired cardiomyocytes from the same preparation (one-way ANOVA, Dunnett's post hoc, n=4 separate cardiomyocyte preparations). (b) Effect of small-molecule FPR agonists (both 1 μM, added on simulated reperfusion) on mouse cardiomyocyte cTnI release subsequent to simulated I–R; ^####P<0.0001 versus sham and *P<0.05 versus vehicle-treated H–R in paired cardiomyocytes from the same preparation (one-way ANOVA, Dunnett's post hoc, n=5 separate cardiomyocyte preparations). (c) Concentration-dependent responses to small-molecule FPR agonists Cmpd 17b (n=4) and Cmpd43 (n=5) in primary rat cardiomyocytes; *P<0.05 versus lowest concentration studied (two-way repeated measures ANOVA, Tukey's post hoc). Effect of Cmpd17b and Cmpd43 (both 10 μM) on TGF-β stimulation of cardiofibroblast. (d) Pro-fibrotic CTGF and (e) pro-inflammatory IL-1β expression; ^#P<0.05, ^##P<0.01 versus sham and *P<0.05 versus TGF-β stimulation in paired cardiofibroblasts from the same preparation, on one-way ANOVA with Dunnett's post hoc test (n per group indicated below the x axis). Results expressed as mean±s.e.m. Controls (open symbols/bars); H–R or TGF-β (black symbols/bars); Cmpd17b (blue symbols/bars); Cmpd43 (red symbols/bars).

Inline graphic — (a) Effect of small-molecule FPR agonists (both 1 μM, added on reoxygenation) on rat cardiomyocyte cTnI release subsequent to H–R; ^##P<0.01 versus sham and *P<0.05 versus vehicle-treated H–R in paired cardiomyocytes from the same preparation (one-way ANOVA, Dunnett's post hoc, n=4 separate cardiomyocyte preparations). (b) Effect of small-molecule FPR agonists (both 1 μM, added on simulated reperfusion) on mouse cardiomyocyte cTnI release subsequent to simulated I–R; ^####P<0.0001 versus sham and *P<0.05 versus vehicle-treated H–R in paired cardiomyocytes from the same preparation (one-way ANOVA, Dunnett's post hoc, n=5 separate cardiomyocyte preparations). (c) Concentration-dependent responses to small-molecule FPR agonists Cmpd 17b (n=4) and Cmpd43 (n=5) in primary rat cardiomyocytes; *P<0.05 versus lowest concentration studied (two-way repeated measures ANOVA, Tukey's post hoc). Effect of Cmpd17b and Cmpd43 (both 10 μM) on TGF-β stimulation of cardiofibroblast. (d) Pro-fibrotic CTGF and (e) pro-inflammatory IL-1β expression; ^#P<0.05, ^##P<0.01 versus sham and *P<0.05 versus TGF-β stimulation in paired cardiofibroblasts from the same preparation, on one-way ANOVA with Dunnett's post hoc test (n per group indicated below the x axis). Results expressed as mean±s.e.m. Controls (open symbols/bars); H–R or TGF-β (black symbols/bars); Cmpd17b (blue symbols/bars); Cmpd43 (red symbols/bars).